Corcept Therapeutics (CORT) Receivables (2012 - 2026)

Corcept Therapeutics has reported Receivables for 15 years, with the latest figure at $81.4 million in Q2 2026.

• Quarterly Receivables rose 18.57% year-over-year to $81.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $81.4 million (up 18.57% YoY) and the FY2025 annual result came in at $63.9 million, up 59.81% from the prior year.
• Receivables improved to $81.4 million in Q2 2026 per CORT's latest filing, from $39.1 million in the prior quarter.
• Over five years, Receivables peaked at $81.4 million in Q2 2026 and troughed at $28.2 million in Q1 2022.
• A 5-year average of $52.2 million and a median of $48.1 million in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2025 and 2026: Receivables soared 68.4% in 2025, then tumbled 51.17% in 2026.
• Over 5 years, Receivables stood at $45.1 million in 2022, then slipped by 8.73% to $41.1 million in 2023, then surged by 31.26% to $54.0 million in 2024, then grew by 10.76% to $59.8 million in 2025, then jumped by 36.19% to $81.4 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $81.4 million, $39.1 million, and $59.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.